Chimeric Antigen Receptor (CAR) Modified T-Cells for ALL
This information was originally presented on September 19, 2014, at the NCCN 9th Annual Congress: Hematologic Malignancies™ held in New York, New York.
This activity is designed to meet the educational needs of hematologists, oncologists, nurses, pharmacists, and other health care professionals who manage patients with hematologic malignancies.
Following this activity, participants should be able to:
- Analyze the role of CAR T-cells as an adoptive therapy for relapsed/refractory ALL
Jae H. Park, MD
Memorial Sloan Kettering Cancer Center
- 0.50 Participation
- 0.49 Nurse
- 0.50 Pharmacist
- 0.50 Physician